In recent months, newly available literature and breaking discoveries have changed our understanding of treatment options, prognostic indicators, and value in various types of sarcoma. Review the latest research breakthroughs involving sarcoma targeted therapies, surgical options, disease burden, and aftercare strategies.
Within the past 3 months, there have been multiple updates to guidelines for a variety of cancers and diseases released. The treatment landscape has been evolving in malignancies such as cervical, vulvar, gastric, lung, skin, and multiple myeloma, as well as diabetes. The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have updated a few of their guidelines to reflect these changes.
B-cell malignancies are among the most deadly and difficult-to-treat blood disorders. Our understanding of treatment options, prognostic indicators, and value in B-cell malignancies is constantly evolving. Within the past 6 months, there have been numerous breakthroughs in B-cell malignancy therapies, biomarkers, prognoses, and mutational understandings. Review the late breakthroughs in this field since the early summer.
Ovarian cancer is one of the leading causes of cancer death among women in the United States. Our understanding of treatment options, prognostic indicators, and value in ovarian cancer is constantly evolving. Review the latest research breakthroughs involving ovarian cancer therapies, biomarkers, prognoses, surgical outcomes, and personalized treatment.